IBIO (IBIO)
$3.26
0.04 (1.07%)
IBIO Stock Quote Delayed 30 Minutes
IBio Stock Is Not Worth a Gamble at This Stage
IBIO stock is in a rough spot with minimal progress in its Covid-19 vaccine and its FastPharming technology.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$3.80
Market Cap
31.85M
PE Ratio
-0.31
EPS
-10.5977
Volume (Avg. Vol.)
788,389
Day's Range
$3.06 - $3.80
52-Week Range
$1.50 - $6.89
Dividend & Yield
N/A (N/A)
IBIO Stock Predictions, Articles, and IBIO News
This Is Why I’d Still Avoid IBio for Now
With no real vaccine news to speak of, I’d avoid the IBIO stock for now. If they can get something going, it may be worth a look.
iBio Will Survive Coronavirus Vaccine Disappointment, But It’s not a ‘Buy’
Investors pondering how a company with a history of moving back-and-forth between micro- and small-cap territory could adequately compete against more well-heeled rivals were right to express those concerns and IBIO stock validated those worries.
iBio Is a Pure Spec Play That Remains a Day Trader’s Delight
IBIO stock will continue to ebb and flow as the pandemic rages on. Day traders should look out for positive clinical trial news as a buy-in signal.
If You’re Not a Speculator, You Should Avoid iBio
After some serious run-ups and drops through 2020, IBIO stock lacks the financial muscle to make it worthy of long-term investment.
Unique Vaccine Solutions Make iBio Stock a Buy Now
A unique plant-based approach makes IBIO stock a quality name for investors looking for a plan on a novel coronavirus vaccine.
Scant Vaccine Hopes Aren’t Enough to Make iBio a Buy
As I detailed earlier this month, there are many pandemic vaccine plays out there with greater chances of success. That's not to say these rival candidates will find success. But, compared to IBIO stock, they look like worthwhile wagers.
There Simply Isn’t Enough Good News for iBio
IBIO stock has faded from its highs with good reason: the company isn't giving investors enough reason to jump in.
IBio is Still Sitting in the Starting Gates of the Vaccine Race
IBIO stock still represents hope for a vaccine. But perhaps it may be time to judge it as a pack member rather than an alpha dog.
Vaccine Wanna-be iBio Stock Remains a Gamble Even After New Partnership
A recent deal on developing a Covid-19 therapy is getting attention but IBIO stock is still a very speculative play in the biopharma space.
iBio Is a Wishful Thinkers Coronavirus Vaccine Bet
IBIO stock isn't the coronavirus vaccine bet investors should pursue, with its candidates in pre-clinical stages showing minimal promise.
Don’t Buy iBio Stock for a Coronavirus Vaccine
Speculators chased IBIO stock up in hopes of a coronavirus vaccine, but long-term investors should stay far away from iBio here.
Don’t Miss the Next Wild Move in iBio Stock
iBio stock offers investors an exciting speculative bet. It already showed its potential this year so it could have repeat performance soon.
Avoid iBio Stock In the Near-Term As Competitors Keep Racing Ahead
At the moment, it’s better to just avoid iBio stock. There are far better opportunities to be found in this market.
iBio Takes Swings, But Hasn’t Found a Pitch It Can Hit
There has been a lot of noise surrounding IBIO stock. But investors need that noise to turn into actionable news to reverse the stock's trend.
IBIO Stock Is a Speculative Bet That Can Double
IBIO stock is a speculative bet that has the potential to double from current levels if there is positive progress related to clinical trials.
As iBio Stock Fades, It’s Time to Look Elsewhere for a Vaccine Play
A few months ago, there was lots of optimism for IBIO stock. But unfortunately, the company has not been able to live up to the lofty expectations.
What iBio Did and Didn’t Do Makes It Suddenly Relevant
One of the earlier Covid-19 darlings, IBIO stock has shed much of its enthusiasm. However, recent news could move the needle again.
Here’s Why IBIO’s Choice of IBIO-201 in the Vaccine Race is a Good Thing
Ibio recently announced IBIO-201 as its coronavirus vaccine candidate. Despite a long road ahead, it’s good news for IBIO stock.
Exclusive Global Agreement Puts a Bullish Slant on iBio
If you've been waiting for a catalyst to buy beaten-down IBIO stock, a worldwide licensing deal should convince you to take action.
